[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342865-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342865-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","soluble-immune-checkpoints-implications-for-cancer-prognosis-and-response-to-immune-checkpoint-therapy-and-conventional-therapies","Soluble immune checkpoints - implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies","","Longitudinal sampling of tumor tissue in many solid-cancer patients is often impractical and may miss therapy-driven changes in tumor–immune interactions. Peripheral blood analyses can reflect the peripheral immunome with technical and practical advantages over repeated tumor biopsies, enabling use of blood-based biomarkers such as immune cell subsets, circulating tumor DNA, and cytokine-like protein analytes. This review summarizes literature on nine soluble immune checkpoints (sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, sHVEM) and evaluates their potential as biomarkers of response to immune checkpoint inhibitors and conventional therapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/soluble-immune-checkpoints-implications-for-cancer-prognosis-and-response-to-immune-checkpoint-therapy-and-conventional-therapies/342865/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/soluble-immune-checkpoints-implications-for-cancer-prognosis-and-response-to-immune-checkpoint-therapy-and-conventional-therapies/342865.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are peripheral blood analyses considered useful for studying immune responses in solid cancers?","Question",{"text":63,"@type":64},"Peripheral blood can provide information about the peripheral immunome and offers practical advantages over tumor biopsies, including non-invasiveness, lower risk, and the ability to sample repeatedly across time points.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What kinds of blood-based biomarkers are commonly used in this context?",{"text":68,"@type":64},"Common biomarkers include immune cell subsets, neutrophil-to-lymphocyte ratio (NLR), circulating tumor DNA, and protein analytes such as cytokines.",{"name":70,"@type":61,"acceptedAnswer":71},"Which soluble immune checkpoints are covered in the review?",{"text":72,"@type":64},"The review discusses nine soluble immune checkpoints: sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, and sHVEM.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342865,1791139941,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Pitts et al. J Exp Clin Cancer Res (2024) 43:155 [https://doi.org/10.1186/s13046-024-03074-z](https://doi.org/10.1186/s13046-024-03074-z)  \nJournal of Experimental & Clinical Cancer Research  \n REVIEW Open Access  \nSoluble immune checkpoints: implications   for cancer prognosis and response to immune checkpoint therapy and conventional therapies  \nStephanie C. Pitts 1, Jeffrey Schlom1* and Renee N. Donahue 1  \nAbstract  \nLongitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may not capture the plasticity of interactions between the tumor and immune system under selective pressure of a given therapy. Peripheral blood analyses provide salient information about the human peripheral immunome while offering technical and practical advantages over traditional tumor biopsies, and should be utilized where possible alongside interrogation of the tumor. Some common blood-based biomarkers used to study the immune response include immune cell subsets, circulating tumor DNA, and protein analytes such as cytokines. With the recent explosion of immune checkpoint inhibitors (ICI) as a modality of treatment in multiple cancer types, soluble immune checkpoints have become a relevant area of investigation for peripheral immunebased biomarkers. However, the exact functions of soluble immune checkpoints and their roles in cancer for the most part remain unclear. This review discusses current literature on the production, function, and expression of nine soluble immune checkpoints – sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, and sHVEM – in patients with solid tumors, and explores their role as biomarkers of response to ICI as well as to conventional therapies (chemotherapy, radiotherapy, targeted therapy, and surgery) in cancer patients.  \nKeywords Peripheral immunome, Blood analyses, Soluble immune checkpoints, Biomarkers, Immune checkpoint inhibitors, Conventional cancer therapies  \nIntroduction  \nPeripheral blood analyses provide salient information about the human peripheral immunome while offering technical and practical advantages over tumor biopsies [1–5]. Tumor biopsies have been traditionally analyzed for protein expression and/or tumor mutational burden (TMB) to identify biomarkers of treatment response [1]. However, tumor specimens often do not account for intratumoral heterogeneity or heterogeneity between  \n*Correspondence: Jeffrey Schlom [schlomj@mail.nih.gov](schlomj@mail.nih.gov)  \n1 Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA  \nthe primary tumor and metastases, and are difficult to obtain at multiple time points to assess changes overtime [1, 2, 4]. Practically, tumor biopsies are expensive and can cause both treatment delays and the potential risk of adverse events [2]. On the other hand, obtaining blood from patients is non-invasive, low-risk, and can be performed repeatedly over multiple time points [1–5]. In recent years, an effort has been made to develop bloodbased biomarkers in cancer patients to study the systemic effects of a given therapy on the immune system; when possible, these studies should be used to complement methods that directly interrogate the tumor and tumor microenvironment. Some common blood-based biomarkers include immune cell subsets, the neutrophilto-lymphocyte ratio (NLR), circulating tumor DNA, and  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party materia","cbCail3KVsIxYice","https://ap.wps.com/l/cbCail3KVsIxYice","pdf",3418605,32,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why are peripheral blood analyses considered useful for studying immune responses in solid cancers?\",\"answer\":\"Peripheral blood can provide information about the peripheral immunome and offers practical advantages over tumor biopsies, including non-invasiveness, lower risk, and the ability to sample repeatedly across time points.\"},{\"question\":\"What kinds of blood-based biomarkers are commonly used in this context?\",\"answer\":\"Common biomarkers include immune cell subsets, neutrophil-to-lymphocyte ratio (NLR), circulating tumor DNA, and protein analytes such as cytokines.\"},{\"question\":\"Which soluble immune checkpoints are covered in the review?\",\"answer\":\"The review discusses nine soluble immune checkpoints: sPD-L1, sPD-1, sCTLA4, sCD80, sTIM3, sLAG3, sB7-H3, sBTLA, and sHVEM.\"}]","Soluble immune checkpoints - implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies | PDF",1790048448,81,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4cbebf2bc22a39b297c5f55e8b9478b.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9e686e227745831f4c43ab943fefffe.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8c097ba280df6f485e0ab623aea692d.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/144b98b1ef7afdf7add4afae292a0e62.webp",980,1301]